logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
返回期刊详情
L

lung cancer: targets and therapy

IF
论文数12
被引数
期刊论文 12
发表时间
delete
Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access Challenges舒沃捷仑在EGFR外显子20插入型NSCLC中的应用：获批但不可用——实际剂量选择考量与真实世界获取挑战
deletelung cancer: targets and therapy
IF0
delete2026-05-28
delete0
deleteOAAI
deleteKim Abbegail Tan Aldecoa; Zhaohui Liao Arter; Sai-Hong Ignatius Ou; Misako Nagasaka
delete分享
delete收藏
HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib – A Case ReportHER2-ADC和HER2-TKI克服了作为佐格替尼获得性耐药的HER2扩增——病例报告
deletelung cancer: targets and therapy
IF0
delete2026-05-14
delete0
deleteOAAI
deleteMisako Nagasaka; Zhaohui L Arter; Cathleen J Park; Akshat Sarkari; Sai-Hong Ignatius Ou
delete分享
delete收藏
Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer基于NGS的MET扩增评估中基因拷贝数阈值的探索性识别及在非小细胞肺癌中与MET抑制剂疗效的临床相关性
deletelung cancer: targets and therapy
IF0
delete2026-05-08
delete0
deleteOAAI
deleteSi-Yang Maggie Liu; Zhi Xie; Lixu Yan; Guang-Ling Jie; Jia-Yi Deng; Qingling Zhang; Zhan Huang; Jin Wang; Zhou Zhang; Yang Shao; Hao Meng; Yan Zhang; Xu-Chao Zhang; Hua-Jun Chen; Wen-Zhao Zhong; Qing Zhou; Yi-Long Wu
delete分享
delete收藏
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China中国人群中表皮生长因子受体（EGFR）突变阳性晚期非小细胞肺癌（NSCLC）患者接受阿法替尼作为一线治疗的真实世界前瞻性观察研究
deletelung cancer: targets and therapy
IF0
delete2026-02-18
delete0
deleteOAAI
deleteJianying Zhou; Yongsheng Wang; Jiewen Peng; Ke-Jing Tang; Jun Wu; Yajuan Chen; Zhiyi Xue; Yi-Long Wu
delete分享
delete收藏
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung CancerClaudin-3表达降低与非小细胞肺癌的不良肿瘤特征和不良预后相关
deletelung cancer: targets and therapy
IF0
delete2026-01-06
delete0
deleteOAAI
deleteNina Schraps; Martin Reck; Birgit Hantzsch-Kuhn; Till Olchers; David Benjamin Ellebrecht; Katharina Möller; Christoph Fraune; Maximilian Lennartz; Florian Lutz; Martina Kluth; Georgia Makrypidi-Fraune; Ronald Simon; Guido Sauter; Stefan Steurer; Sönke Von Weihe
delete分享
delete收藏
Incretin Receptor Agonist; Semaglutide; as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report胰高血糖素样肽受体激动剂；Semaglutide；作为治疗Alectinib诱导的过度体重增加的案例报告。
deleteLung Cancer: Targets and Therapy
IF0
delete2025-12-25
delete0
deleteOAAI
deleteAlexandria TM Lee; Cathleen June Park; Zhaohui Liao Arter; Misako Nagasaka; Sai-Hong Ignatius Ou
delete分享
delete收藏
Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC – Insights From Genomics; Proteomics; and Metabolomics整合多组学方法预测NSCLC中免疫检查点抑制剂反应——来自基因组学、蛋白质组学和代谢组学的见解
deleteLung Cancer: Targets and Therapy
IF0
delete2025-12-16
delete0
deleteOAAI
deleteEman Elayeh; Shereen M Aleidi; Orwa Aboud; Mohammad H Semreen; Yasser K Bustanji; Lina A Dahabiyeh
delete分享
delete收藏
Pulmonary Nodular Lymphoid Hyperplasia: Reviewing a Lung Cancer Mimicker肺结节性淋巴组织增生：回顾一种肺癌的模拟疾病
deleteLung Cancer: Targets and Therapy
IF0
delete2025-12-10
delete0
deleteOAAI
deleteGabriela Schneider Galvão; Jônatas Fávero Prietto dos Santos; Ying-Han R Hsu; Patrik Rogalla
delete分享
delete收藏
A Concise Review of the Approved MET TKIs (Savolitinib; Gumarontinib; Vebreltinib; Tepotinib; Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025中国批准的MET TKIs（Savolitinib；Gumarontinib；Vebreltinib；Tepotinib；Capmatinib）在2025年左右针对MET外显子14跳跃突变（METex14+）非小细胞肺癌的简要综述
deleteLung Cancer: Targets and Therapy
IF0
delete2025-10-31
delete0
deleteOAAI
deleteYanyan Hu; Sai-Hong Ignatius Ou
delete分享
delete收藏
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib使用Gilteritinib成功并持续控制长期（>24个月）疾病，在一名有脑转移且对多种ALK TKIs耐药的ALK+ NSCLC患者中的病例报告及Gilteritinib相关文献综述。
deleteLung Cancer: Targets and Therapy
IF0
delete2025-10-22
delete0
deleteOAAI
deleteSai-Hong Ignatius Ou; Cathleen June Park; Zhaohui Liao Arter; Misako Nagasaka
delete分享
delete收藏
Tumor Heterogeneity and Plasticity in Small Cell Lung Cancer小细胞肺癌中的肿瘤异质性与可塑性
deleteLung Cancer: Targets and Therapy
IF0
delete2025-10-10
delete0
deleteOAAI
deleteGina N Duronio, Julien Sage
delete分享
delete收藏
Emerging Targets in Non-Small Cell Lung Cancer非小细胞肺癌中的新兴靶点
deleteLung Cancer: Targets and Therapy
IF0
delete2025-09-06
delete0
deleteOAAI
deleteJing Wang, Layana Biglow, Megan Baumgart
delete分享
delete收藏